ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Staphylococcus epidermidis Strain Topical Ointment ATR04-484

Also written as “ATR04-484” and “ATR-04”.

Its studies are mostly in Exanthema · Rosacea, led by Azitra.

Furthest: phase 2, since Jan 14, 20212 company-led studies, 1 open or runningNext primary completion: Jul 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Azitra21 open or runningphase 2since Jan 14, 2021Jan 14, 2021Jul 15, 2027phase 2 · NCT06830863

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2021First study: phase 2 study in RosaceaFirst studyNCT04731259
  2. Feb 12, 2025Phase 2 study in EGFR Inhibitor-associated RashNCT06830863 · 32 planned · United States

Ahead

  1. Jul 15, 2027Primary completion: phase 2 study in EGFR Inhibitor-associated RashNCT06830863

TargetBeta

EGFR →read by rule
“A topical ointment formulation comprised of an engineered Staphylococcus epidermidis strain SE484, derived from a healthy human volunteer, for the potential treatment of epidermal growth factor receptor (EGFR) inhibitor-associated dermal toxicities”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06830863EGFR Inhibitor-associated Rash · United States2RecruitingJul 15, 202732
NCT04731259Rosacea2WithdrawnJan 20260

How it is read

Names in the registry

  • “ATR04-484”, 1 entry
  • “ATR-04”, 1 entry

Codes read as this program: ATR04.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.